A
Anna R. Carta
Researcher at University of Cagliari
Publications - 57
Citations - 2666
Anna R. Carta is an academic researcher from University of Cagliari. The author has contributed to research in topics: Dopamine & Neuroinflammation. The author has an hindex of 26, co-authored 54 publications receiving 2255 citations. Previous affiliations of Anna R. Carta include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The 6-hydroxydopamine model of Parkinson's disease.
TL;DR: The present review will examine the main features of 6-OHDA models, namely the mechanisms of neurotoxin-induced neurodegeneration as well as several behavioural deficits and motor dysfunctions, including the priming model, modeled by this means.
Journal ArticleDOI
Expression of functional leptin receptors in rodent Leydig cells
Massimiliano Caprio,Andrea M. Isidori,Anna R. Carta,Costanzo Moretti,Maria L. Dufau,Andrea Fabbri +5 more
TL;DR: Findings show that leptin has direct, receptor-mediated actions on rodent Leydig cells in culture, at concentrations within the range of obese men, and indicate that leptin action on steroidogenesis occurs downstream of progesterone synthesis.
Journal ArticleDOI
Microglial phenotypes in Parkinson's disease and animal models of the disease.
TL;DR: This review will critically address current knowledge on the activation states of microglia as well as microglial phenotypes found in PD and in animal models of PD, focusing on the expression of surface molecules aswell as pro-inflammatory and anti-inflammatory cytokine production during the disease process.
Journal ArticleDOI
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
TL;DR: The results support the use of PPAR‐γ agonists as a putative anti‐inflammatory therapy aimed at arresting PD progression, and suggest that assessment in PD clinical trials is warranted.
Book ChapterDOI
Adenosine A2A Receptors and Parkinson’s Disease
TL;DR: In clinical trials, the A(2A)AR antagonist istradefylline reduces "off" time in patients with PD receiving optimal dopaminergic therapy, however, these effects have proven difficult to demonstrate on a consistent basis, and further clinical trials are required to establish the clinical utility of this drug class.